Abstract
Androgen deprivation therapy (ADT) can result in a range of adverse symptoms that
reduce patients' quality of life. Careful patient counseling on the likely clinical
outcomes and adverse effects is therefore vital. The present systematic review was
undertaken to identify and characterize all the tools used for the prediction of clinical
and patient-reported outcome measures (PROMs) in patients with prostate cancer undergoing
ADT. PubMed and EMBASE were systematically searched from 2007 to 2016. Search terms
related to the inclusion criteria were: prostate cancer, clinical outcomes, PROMs,
ADT, and prognosis. Titles and abstracts were reviewed to find relevant studies, which
were advanced to full-text review. The reference lists were screened for additional
studies. The Centre for Evidence Based Medicine critical appraisal of prognostic studies
tool was applied. The search strategy identified 8755 studies. Of the 8755 studies,
22 on clinical outcomes were identified. However, no studies of PROMs were found.
Nine tools could be used to predict clinical outcomes in treatment-naive patients
and 10 in patients with recurrence. The Japan Cancer of the Prostate Risk Assessment
(J-CAPRA) nomogram was the best performing and validated tool for the prediction of
clinical outcomes in treatment-naive patients, and the Chi and Shamash prognostic
indexes have been validated for use in patients with castration-resistant disease
in different clinical contexts. Using the J-CAPRA nomogram should help clinicians
deliver accurate, evidence-based counseling to patients undergoing primary ADT. A
strong need exists for primary studies that derive and validate tools for the prediction
of PROMs in patients undergoing ADT under any circumstance because these are currently
absent from the literature.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The global burden of cancer 2013.JAMA Oncol. 2015; 1: 505-527
- Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.Int J Cancer. 2015; 136: E359-E386
- Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association.Int J Urol. 2005; 12: 46-61
- Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.J Clin Oncol. 2014; 32: 1324-1330
- Quality of life issues in men undergoing androgen deprivation therapy: a review.Asian J Androl. 2012; 14: 226-231
- Quality of life in prostate cancer patients taking androgen deprivation therapy.J Am Geriatr Soc. 2006; 54: 85-90
- Clinicians versus nomogram: predicting future technetium-99m bone scan positivity in patients with rising prostate-specific antigen after radical prostatectomy for prostate cancer.Urology. 2013; 81: 956-961
- Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer.BJU Int. 2007; 100: 1254-1258
- Patient reported outcomes following radiation therapy in men with prostate cancer: a systematic review of prognostic tool accuracy and validity.Int J Radiat Oncol Biol Phys. 2017;
O'Callaghan ME, Raymond E, Campbell JM, et al. Tools for predicting patient reported outcomes in prostate cancer patients undergoing radical prostatectomy: a systematic review of prognostic accuracy and validity. Prostate Cancer Prostatic Dis, in press.
- An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review.Radiat Oncol. 2017; 12: 56
- An updated catalog of prostate cancer predictive tools.Cancer. 2008; 113: 3075-3099
- Development of an international prostate cancer outcomes registry.BJU Int. 2016; 117: 60-67
- Critical appraisal of prognostic studies.University of Oxford, Oxford, UK2016
- Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data.Prostate. 2016; 76: 48-57
- Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.J Clin Oncol. 2009; 27: 4306-4313
- Predicting survival of patients with node-positive prostate cancer following multimodal treatment.Eur Urol. 2014; 65: 554-562
- Detectable prostate-specific antigen nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.Eur Urol. 2014; 65: 620-627
- Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy.BMC Cancer. 2016; 16: 329
- Pretreatment plasma fibrinogen as an independent prognostic indicator of prostate cancer patients treated with androgen deprivation therapy.Prostate Cancer Prostatic Dis. 2016; 19: 209-215
- Prostate cancer-specific survival in men treated with hormonal therapy after failure of radical prostatectomy.Eur Urol. 2007; 52: 446-452
- A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02.Clin Cancer Res. 2014; 20: 6379-6388
- Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model.Jpn J Clin Oncol. 2014; 44: 263-269
- Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.Int J Urol. 2013; 20: 708-714
- The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy.J Cancer Res Clin Oncol. 2014; 141: 495-503
- A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score.Jpn J Clin Oncol. 2015; 45: 197-201
- 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy.J Nucl Med. 2014; 55: 233-241
- The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.Prostate. 2015; 75: 1499-1509
- Bone scan index predicts outcome in patients with metastatic hormone-sensitive prostate cancer.BJU Int. 2016; 117: 748-753
- Bone scan index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy.EJNMMI Res. 2013; 3: 9
- Improvement of a predictive model of castration-resistant prostate cancer: functional genetic variants in TGFbeta1 signaling pathway modulation.PLoS One. 2013; 8: e72419
- Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the Glass model and development of a novel simplified prognostic model.Eur Urol. 2015; 68: 196-204
- Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.Ann Oncol. 2014; 25: 657-662
- A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer.Cancer. 2010; 116: 3595-3602
- External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone.Eur Urol. 2014; 66: 8-11
- A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.Ann Oncol. 2016; 27: 454-460
- Comparison of two ordinal prediction models: a cancer staging system example.Clin Trials. 2015; 12: 342-347
- The FRAX score as a tool for estimating fracture risk in patients with advanced prostate cancer on androgen-deprivation therapy compared to the conventional T-score.J Clin Oncol. 2014; 32 (abstract e16023)
- Development and validation of a prognostic index for fracture risk in older men undergoing prostate cancer treatment.J Clin Oncol. 2014; 32 (abstract 5056): 5s
- Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapy.Urology. 2014; 84: 164-168
- Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement.Ann Intern Med. 2015; 162: 55-63
- Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration.Ann Intern Med. 2015; 162: W1-W73
- Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement.Br J Cancer. 2015; 112: 251-259
- Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement.BMC Med. 2015; 13: 1
- Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement.BMJ. 2015; 350: g7594
- Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement.Eur Urol. 2015; 67: 1142-1151
- Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement.Br J Surg. 2015; 102: 148-158
- Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD).Ann Intern Med. 2015; 162: 735-736
- New guideline for the reporting of studies developing, validating, or updating a multivariable clinical prediction model: the TRIPOD statement.Adv Anat Pathol. 2015; 22: 303-305
Article info
Publication history
Published online: March 29, 2017
Accepted:
March 18,
2017
Received in revised form:
March 17,
2017
Received:
February 17,
2017
Identification
Copyright
© 2017 Elsevier Inc. All rights reserved.
